Prognostic significance of a novel indicator (PSA_postd3/PSA_pre) for PSA recurrence in patients after radical prostatectomy

References

• Ward JF, Blute ML, Slezak J, Bergstralh EJ, Zincke H. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003;170(5):1872–1876. doi:10.1097/01.ju.0000091876.13656.2e14532796
   PubMed Web of Science ®Google Scholar
• Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. Jama. 1999;281(17):1591–1597.10235151
   PubMed Web of Science ®Google Scholar
• Odisho AY, Washington SL 3rd, Meng MV, Cowan JE, Simko JP, Carroll PR. Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology. 2013;82(1):154–159. doi:10.1016/j.urology.2012.12.06323522995
   PubMed Web of Science ®Google Scholar
• Godoy G, Tareen BU, Lepor H. Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy? Urology. 2009;74(1):167–170. doi:10.1016/j.urology.2008.07.06719406457
   PubMed Web of Science ®Google Scholar
• Inagaki T, Kohjimoto Y, Nishizawa S, et al. PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy. Int J Urol. 2009;16(12):941–946. doi:10.1111/j.1442-2042.2009.02401.x19832922
   PubMed Web of Science ®Google Scholar
• Vollmer RT, Humphrey PA. The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. Am J Clin Pathol. 2001;116(6):864–870. doi:10.1309/7MQ7-MWAR-4W8A-R75F11764075
   PubMed Web of Science ®Google Scholar
• Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010;57(4):622–629. doi:10.1016/j.eururo.2009.03.07719375843
   PubMed Web of Science ®Google Scholar
• Tilki D, Kim SI, Hu B, Dall’Era MA, Evans CP. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015;193(5):1525–1531. doi:10.1016/j.juro.2014.10.08725444980
   PubMed Web of Science ®Google Scholar
• Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317(15):909–916. doi:10.1056/NEJM1987100831715012442609
   PubMed Web of Science ®Google Scholar
• Zattoni F, Piazza R, Vianello R, Garbeglio A, Pagano F. Preoperative and postoperative evaluation of prostate-specific antigen in localized prostatic cancer treated by radical prostatectomy. Eur Urol. 1992;21(Suppl 1):99–101.1385140
   PubMedGoogle Scholar
• panel Npc. NCCN prostate cancer practice guidelines. The National comprehensive cancer network. Version 2.2017. The National Comprehensive Cancer Network Clinical Practice Guidelines; 2017.
   Google Scholar
• Wang H, Gao X, Fang Z, et al. The older the better: the characteristic of localized prostate cancer in Chinese men. Asian J Urol. 2015;2(3):129–132. doi:10.1016/j.ajur.2015.07.00129264132
   PubMedGoogle Scholar
• Turk H, Celik O, Un S, et al. Predictive factors for biochemical recurrence in radical prostatectomy patients. Cent European J Urol. 2015;68(4):404–409. doi:10.5173/ceju.2015.606
   PubMedGoogle Scholar
• Sachdeva A, Veeratterapillay R, Voysey A, et al. Positive surgical margins and biochemical recurrence following minimally-invasive radical prostatectomy - An analysis of outcomes from a UK tertiary referral centre. BMC Urol. 2017;17(1):91. doi:10.1186/s12894-017-0262-y28969608
   PubMedGoogle Scholar
• Garcia-Barreras S, Rozet F, Nunes-Silva I, et al. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy. Clin Transl Oncol. 2018;20(8):1004–1010. doi:10.1007/s12094-017-1812-1.
   Web of Science ®Google Scholar
• Takeuchi H, Ohori M, Tachibana M. Clinical significance of the prostate-specific antigen doubling time prior to and following radical prostatectomy to predict the outcome of prostate cancer. Mol Clin Oncol. 2017;6(2):249–254. doi:10.3892/mco.2016.111628357104
   PubMedGoogle Scholar
• Aguilera A, Banuelos B, Diez J, Alonso-Dorrego JM, Cisneros J, Pena J. Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors. Cent European J Urol. 2015;68(3):302–307. doi:10.5173/ceju.2015.485
   PubMedGoogle Scholar
• Zhang YD, Wu CJ, Bao ML, et al. MR-based prognostic nomogram for prostate cancer after radical prostatectomy. J Magn Reson Imaging. 2017;45(2):586–596. doi:10.1002/jmri.2544127654116
   PubMed Web of Science ®Google Scholar
• Chalieopanyarwong V, Attawettayanon W, Kanchanawanichkul W, Pripatnanont C. The prognostic factors of biochemical recurrence-free survival following radical prostatectomy. Asian Pac J Cancer Prev. 2017;18(9):2555–2559. doi:10.22034/APJCP.2017.18.9.255528952300
   PubMedGoogle Scholar
• Un S, Turk H, Koca O, Divrik RT, Zorlu F. Factors determining biochemical recurrence in low-risk prostate cancer patients who underwent radical prostatectomy. Turk J Urol. 2015;41(2):61–66. doi:10.5152/tud.2015.6562426328203
   PubMed Web of Science ®Google Scholar
• Da Cruz JAS, Passerotti CC, Dos Reis ST, et al. Is age an independent factor for prostate cancer? A paired analysis. Curr Urol. 2017;9(4):183–187. doi:10.1159/00044713828413378
   PubMedGoogle Scholar
• Yossepowitch O, Briganti A, Eastham JA, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014;65(2):303–313. doi:10.1016/j.eururo.2013.07.03923932439
   PubMed Web of Science ®Google Scholar
• Vesely S, Jarolim L, Duskova K, Schmidt M, Dusek P, Babjuk M. The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy. BMC Urol. 2014;14:79. doi:10.1186/1471-2490-14-7925277310
   PubMed Web of Science ®Google Scholar
• Audenet F, Seringe E, Drouin SJ, et al. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol. 2012;30(2):239–244. doi:10.1007/s00345-011-0707-y21638225
   PubMed Web of Science ®Google Scholar
• Malik RD, Goldberg JD, Hochman T, Lepor H. Three-year postoperative ultrasensitive prostate-specific antigen following open radical retropubic prostatectomy is a predictor for delayed biochemical recurrence. Eur Urol. 2011;60(3):548–553. doi:10.1016/j.eururo.2011.05.03621652145
   PubMed Web of Science ®Google Scholar
• Skove SL, Howard LE, Aronson WJ, et al. Timing of prostate-specific antigen nadir after radical prostatectomy and risk of biochemical recurrence. Urology. 2017;108:129–134. doi:10.1016/j.urology.2017.07.00928735016
   PubMed Web of Science ®Google Scholar
• Blanchard P, Bakkour M, De Crevoisier R, et al. Early PSA level decline is an independent predictor of biochemical and clinical control for salvage postprostatectomy radiotherapy. Urol Oncol. 2015;33(3):108.e115–e120. doi:10.1016/j.urolonc.2014.07.020
   Web of Science ®Google Scholar
• Kilic S, Yalcinkaya S, Guntekin E, Kukul E, Deger N, Sevuk M. Determination of the site of metabolism of total, free, and complexed prostate-specific antigen. Urology. 1998;52(3):470–473.9730463
   PubMed Web of Science ®Google Scholar
• Jhaveri FM, Zippe CD, Klein EA, Kupelian PA. Biochemical failure does not predict overall survival after radical prostatectomy for localized prostate cancer: 10-year results. Urology. 1999;54(5):884–890.10565752
   PubMed Web of Science ®Google Scholar
• Vassilikos EJ, Yu H, Trachtenberg J, et al. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clin Biochem. 2000;33(2):115–123.10751589
   PubMed Web of Science ®Google Scholar
• Dillioglugil O, Leibman BD, Kattan MW, Seale-Hawkins C, Wheeler TM, Scardino PT. Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology. 1997;50(1):93–99. doi:10.1016/S0090-4295(97)00106-49218025
   PubMed Web of Science ®Google Scholar